Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

V. Scagliotti, Giorgio; Parikh, Purvish; von Pawel, Joachim; Biesma, Bonne; Vansteenkiste, Johan; Manegold, Christian; Serwatowski, Piotr; Gatzemeier, U.; Digumarti, Raghunadharao; Zukin, Mauro; S. Lee, Jin; Mellemgaard, Anders; Park, Keunchil; Patil, Shehkar; Rolski, Janusz; Göksel, Tuncay; de Marinis, Filippo; Simms, Lorinda; P. Sugarman, Katherine; R. Gandara, David

doi:10.1200/jco.22.02544

Public

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • May 5, 2023

Authors:

Giorgio V. Scagliotti

Purvish Parikh

Joachim von Pawel

Abstract

PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS This noninferiority, phase III, randomized study com...

Subject

Pemetrexed

Gemcitabine

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!